Zacks.com on MSN9h
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Based on the latest available data, ACLX has gained about 78.7% so far this year. Meanwhile, the Medical sector has returned an average of 4% on a year-to-date basis. This means that Arcellx, Inc. is ...
Arcellx price target raised to $115 from $91 at Piper Sandler
Piper Sandler raised the firm’s price target on Arcellx (ACLX) to $115 from $91 and keeps an Overweight rating on the shares following Q3 ...
Arcellx Inc’s Promising Clinical Data and Safety Profile Drive Buy Rating
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on ACLX stock, giving a Buy rating on November 6. Tyler Van Buren has ...
Arcellx (NASDAQ:ACLX) Given New $106.00 Price Target at Morgan Stanley
Arcellx (NASDAQ:ACLX – Get Free Report) had its price target increased by Morgan Stanley from $81.00 to $106.00 in a research ...
Hosted on MSN12h
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript
The median progression-free survival and overall survival had not yet been reached. Additionally, Arcellx announced yesterday that updated data from the Phase 1 study will be presented at ASH. In the ...
Automatic Data Processing (NASDAQ:ADP) Price Target Raised to $325.00 at Barclays
Automatic Data Processing (NASDAQ:ADP – Free Report) had its price objective lifted by Barclays from $310.00 to $325.00 in a ...